logo

BIOA

BioAge LabsยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

Key Stats

0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000

About BIOA

Bioage Labs, Inc.

A biotech company focused on assessing and optimizing biological age

Pharmaceutical
04/01/2015
09/26/2024
NASDAQ Stock Exchange
62
12-31
Common stock
5885 Hollis St, Suite 370, Emeryville, CA 94608
--
BioAge Labs, Inc., was incorporated in Delaware on April 1, 2015. They are a clinical-stage biopharmaceutical company developing product candidates for the treatment of metabolic diseases such as obesity by targeting the biology of human aging. Their technology platform and differentiated human datasets allow them to identify promising targets based on insights into the molecular changes that drive aging. Their main focus is metabolic disease, one of the biggest healthcare challenges in the world.

Company Financials

EPS

BIOA has released its 2025 Q3 earnings. EPS was reported at -0.56, versus the expected -0.51, missing expectations. The chart below visualizes how BIOA has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

BIOA has released its 2025 Q3 earnings report, with revenue of 2.05M, reflecting a YoY change of NaN%, and net profit of -20.17M, showing a YoY change of 13.82%. The Sankey diagram below clearly presents BIOA's revenue sources and cost distribution.

Forecast

Wall Street Opinions

Price Target

Volume Profile

Trade Flow Insight

Seasonals

Community Forum

Loading...

Related News

No articles available

Related Symbols

You can ask Aime